Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs P Mease on BE MOBILE 1 & 2 BKZ 160 mg q4w vs PBO 254 pts w nr-axSpA, 332 w AS Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16 @RheumNow https://t.co/nxZFSrb2XK